GPOs respond to new market
Group purchasing organizations grew in numbers, consolidated and expanded services last year, according to SMG, a Chicago-based market research and consulting firm.
Group purchasing organizations grew in numbers, consolidated and expanded services last year, according to SMG, a Chicago-based market research and consulting firm.
SMG data reveals that the total number of multihospital systems and GPOs grew from 582 in 1995 to 720 in 1996.
The 20 largest "super groups" claim access to 87% of all U.S. hospitals and staffed beds - 96% of all acute care hospitals and beds. These groups offer high purchasing volumes and compliance to health care product manufacturers and distributors in exchange for contracted discounts, value-added services and other improved contract terms. In addition to the super-group mergers, smaller regional alliances are jumping on the bandwagon and actively joining with some of the national groups.
SMG said 420 groups have contracts with alternate health care sites, a 16% increase from the previous year. In addition to the increased contracts with surgery centers, health maintenance organizations and other sites, contracts for capital equipment, consulting services and equipment services are becoming increasingly common. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
